Emtricitabine/tenofovir disoproxil (TEVA®)

Assessment Status Rapid review complete
Drug Emtricitabine/tenofovir disoproxil
Brand TEVA®
Indication For pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk
Assessment Process
Rapid review commissioned 11/12/2017
Rapid review completed 21/12/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended